A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Ascending Doses of G1T48 in Women With Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer
Phase of Trial: Phase I/II
Latest Information Update: 06 Aug 2018
At a glance
- Drugs G1T-48 (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions; First in man
- Sponsors G1 Therapeutics
- 09 May 2018 Status changed from not yet recruiting to recruiting.
- 03 May 2018 According to a G1 Therapeutics media release, the company anticipates to initiate the trial in the second quarter of 2018.
- 06 Mar 2018 Status changed from planning to not yet recruiting.